BC99 Probiotic: Major Changes in Gut Bacteria Linked to Better Mood Ep. 1263 Oct 2025

A recent 8-week, randomized, double-blind, placebo-controlled pilot study explored the effects of the probiotic strain Weizmannia coagulans BC99 on symptoms of anxiety and depression. The trial involved 79 participants who received either 3 grams of the BC99 probiotic, containing 5 billion CFUs, or a placebo daily. While both groups saw improvements, the BC99 group experienced a greater reduction in depression and anxiety scores (HAMD and HAMA scales) compared to the placebo group, though this difference was not statistically significant.
More significantly, the study found that BC99 supplementation led to several key biological changes. It helped regulate inflammatory cytokines, notably increasing the anti-inflammatory IL-10. Participants taking BC99 also showed a significant increase in the calming neurotransmitter gamma-aminobutyric acid (-GABA). Furthermore, the probiotic altered the gut microbiome by increasing the abundance of beneficial bacteria like Faecalibactrium, Megamonas, Dialister, and Agathobacter, while also boosting the production of beneficial short-chain fatty acids (SCFAs) like propionic and isobutyric acid. These findings suggest BC99 may alleviate symptoms of anxiety and depression by positively influencing the gut-brain axis.
3. Disclaimers
• This information is for educational purposes only and should not be interpreted as medical advice.
• The study discussed was a clinical pilot study conducted on human adults. Further research may be needed to confirm these findings.
• Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, especially if you have a medical condition or are taking medications.
• This channel does not provide medical advice.
#WeizmanniaCoagulans #Probiotics #GutBrainAxis #AnxietyResearch #BC99
Tie S, Pan Y, Pang C, Saman A, Dong Y, Fang S, Zhu J, Wu Y, Gu S. The Impact of Weizmannia coagulans BC99 on Anxiety and Depression: An 8-Week Clinical Pilot Study Through the Gut Microbiota–Brain Axis. Nutrients. 2025; 17(19):3087. https://doi.org/10.3390/nu17193087

Alchepharma,Ralph Turchiano,citation,research,study,Weizmannia coagulans BC99,probiotics for anxiety,probiotics for depression,gut microbiota-brain axis,psychobiotics,Hamilton Depression Rating Scale,short-chain fatty acids,gamma-aminobutyric acid,inflammatory cytokines,gut dysbiosis,mental health supplements,Faecalibactrium,neurotransmitter regulation,gut health,microbiome and mood,clinical nutrition,bacterial therapy